Is Xenetic Biosciences Inc (XBIO) overvalued? · rev $2.5M
Xenetic Biosciences Inc (XBIO) is a biotechnology company listed on US.
This page asks whether Xenetic Biosciences Inc (XBIO) looks expensive on cached numbers — not a short thesis.
Latest reported XBIO revenue for 2024-12-31 was $2.5M. Net income was -$4.0M. Revenue was down 1.6% from 2023-12-31 to 2024-12-31. XBIO currently screens at market cap $5.7M.
XBIO currently screens at market cap $5.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next XBIO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the XBIO stock page for the full model, not this heading.
Not investment advice.